Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient

Pharmacotherapy

Volumn 35, Issue 4, 2015, Pages e32-e36

  Cies, Jeffrey J ^a,b,c   Moore, Wayne S ^c   Calaman, Sharon ^a,b   Brown, Melandee ^a,b   Narayan, Prithvi ^a,b   Parker, Jason ^a,b   Chopra, Arun ^d,e  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

carbapenem; continuous infusion; meropenem; pediatric; pharmacodynamics; pharmacokinetic; ventriculitis

Indexed keywords

AMIKACIN; BACITRACIN; CEFOTAXIME; COTRIMOXAZOLE; MEROPENEM; RIFAMPICIN; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADD ON THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN VENTRICLE PERITONEUM SHUNT; BRAIN VENTRICULITIS; CASE REPORT; CEREBROSPINAL FLUID CULTURE; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CRANIOTOMY; DECREASED APPETITE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GLASGOW COMA SCALE; HUMAN; HYDROCEPHALUS; INTUBATION; IRRITABILITY; LEUKOCYTE; NONHUMAN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SERRATIA INFECTION; SERRATIA MARCESCENS; SERRATIA MARCESCENS VENTRICULITIS; SOMNOLENCE; VENTRICULOSTOMY CATHETER; VOMITING; CEREBRAL VENTRICULITIS; INTRAVENOUS DRUG ADMINISTRATION; SERRATIA INFECTIONS;

ANTI-BACTERIAL AGENTS; CEREBRAL VENTRICULITIS; CHILD, PRESCHOOL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; SERRATIA INFECTIONS; SERRATIA MARCESCENS; THIENAMYCINS;

EID: 84927729718     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1567     Document Type: Article

References (33)

1. Ngo QN, Ranger A, Singh RN, Kornecki A, Seabrook JA, Fraser DD,. External ventricular drains in pediatric patients. Pediatr Crit Care Med 2009; 10: 346-51.
2. Simon TD, Hall M, Riva-Cambrin J, et al. Infection rates following initial cerebrospinal fluid shunt placement across pediatric hospitals in the United States. Clinical article. J Neurosurg Pediatr 2009; 4: 156-65.
3. Adams DJ, Rajnik M,. Microbiology and treatment of cerebrospinal fluid shunt infections in children. Curr Infect Dis Rep 2014; 16: 427.
4. Kestle J, Drake J, Milner R, et al. Long-term follow-up data from the Shunt Design Trial. Pediatr Neurosurg 2000; 33: 230-6.
5. Kestle JR, Drake JM, Cochrane DD, et al. Lack of benefit of endoscopic ventriculoperitoneal shunt insertion: a multicenter randomized trial. J Neurosurg 2003; 98: 284-90.
6. James HE, Walsh JW, Wilson HD, Connor JD, Bean JR, Tibbs PA,. Prospective randomized study of therapy in cerebrospinal fluid shunt infection. Neurosurgery 1980; 7: 459-63.
7. Schreffler RT, Schreffler AJ, Wittler RR,. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J 2002; 21: 632-6.
8. Wong GK, Poon WS, Wai S, Yu LM, Lyon D, Lam JM,. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry 2002; 73: 759-61.
9. Chapman PH, Borges LF,. Shunt infections: prevention and treatment. Clin Neurosurg 1985; 32: 652-64.
10. Tunkel AR, Kaufman BA,. Cerebrospinal fluid shunt infections. In:, Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principle of infectious diseases. Philadelphia: Elsevier, 2005: 1126-11.
11. Cies JJ, Shankar V, Schlichting C, Kuti JL,. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. Pediatr Infect Dis J 2014; 33: 168-73.
12. Cies JJ, Moore MW, Chopra A,. Meropenem Pharmacokinetics in Critically Ill Children Abstract 938 2014. Abstract Presented at the Society of Critical Care Medicine 43rd Annual Congress, San Francisco, CA, January 2014.
13. Limpan J, Udy AA, Roberts JA,. Do we understand the impact of altered physiology, consequent interventions, and resultant clinical scenarios in ICU? The antibiotic story. Anaesth Intensive Care, 2011; 39: 999-1000.
14. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current b-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis, 2014; 58: 1072-83.
15. Cies JJ, Moore WS II, Dickerman MJ, et al. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support. Pharmacotherapy 2014; 34: e175-9.
16. Drusano GL,. Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nat Rev Microbiol, 2004; 2: 289-300.
17. Drusano GL,. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis, 2003; 36: 42-50.
18. Lonsdale DO, Udy AA, Roberts JA, Lipman J,. Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. J Neurosurg 2013; 118: 297-301.
19. Roberts JA, Lipman J,. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med, 2009; 37: 840-51.
20. Pharmaceuticals, A.Z. Meropenem (Merrem) package insert. Wilmington, DE; 2007.
21. Udy A, Boots R, Senthuran S, et al. Augmented creatinine clearance in traumatic brain injury. Anesth Analg, 2010; 111: 1505-10.
22. Udy AA, Roberts JA, Lipman J,. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol, 2011; 7: 539-43.
23. Turnidge JD,. The pharmacodynamics of beta-lactams. Clin Infect Dis, 1998; 27: 10-22.
24. Zhanel GG, Simor AE, Vercaigne LO, et al. Imipenem and meropenem: comparison of in vitro activity, pahrmacokinetics, clinical trials and adverse effects. Can J Infect Dis, 1998; 9: 215-28.
25. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs, 2007; 67: 1027-52.
26. Di Paolo A, Gori G, Tascini C, Danesi R, Del Tacca M,. Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. Clin Pharmacokinet, 2013; 52: 511-42.
27. Nau R, Lassek C, Kinzig-Schippers M, et al. Disposition and elimination of meropenem in cerebrospinal fluid cultures of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother, 1998; 42: 2012-6.
28. Costerton JW, Stewart PS, Greenberg EP,. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
29. Donlan RM,. Role of biofilms in antimicrobial resistance. ASAIO J 2000; 46: S47-52.
30. Qian Z, Sagers RD, Pitt WG,. Investigation of the mechanism of the bioacoustic effect. J Biomed Mater Res 1999; 44: 198-205.
31. Costerton JW, Stewart PS,. Battling biofilms. Sci Am 2001; 285: 74-81.
32. Carmen JC, Roeder BL, Nelson JL, et al. Treatment of biofilm infections on implants with low-frequency ultrasound and antibiotics. Am J Infect Control 2005; 33: 78-82.
33. Rice SA, Koh KS, Queck SY, Labbate M, Lam KW, Kjelleberg S,. Biofilm formation and sloughing in Serratia marcescens are controlled by quorum sensing and nutrient cues. J Bacteriol 2005; 187: 3477-85.